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ABSTRACT Apolipoproteins play a central role in lipoprotein metabolism, and are directly implicated in cardiovascular dis-
eases, but their structural characterization has been complicated by their structural ﬂexibility and heterogeneity. Here we de-
scribe the structural characterization of the N-terminal region of apolipoprotein B (apoB), the major protein component of very
low-density lipoprotein and low-density lipoprotein, in the presence of phospholipids. Speciﬁcally, we focus on the N-terminal
6.4–17% of apoB (B6.4-17) complexed with the phospholipid dimyristoylphosphatidylcholine in vitro. In addition to circular di-
chroism spectroscopy and limited proteolysis, our strategy incorporates nanogold-labeling of the protein in the reconstituted
lipoprotein complex followed by visualization and molecular weight determination with scanning transmission electron micros-
copy imaging. Based on the scanning transmission electron microscopy imaging analysis of ;1300 individual particles where
the B6.4-17 is labeled with nanogold through a six-His tag, most complexes contain either two or three B6.4-17 molecules.
Circular dichroism spectroscopy and limited proteolysis of these reconstituted particles indicate that there are no large con-
formational changes in B6.4-17 upon lipoprotein complex formation. This is in contrast to the large structural changes that occur
during apolipoprotein A-I-lipid interactions. The method described here allows a direct measurement of the stoichiometry and
molecular weight of individual particles, rather than the average of the entire sample. Thus, it represents a useful strategy to
characterize the structure of lipoproteins, which are not structurally uniform, but can still be deﬁned by an ensemble of related
patterns.
INTRODUCTION
The transportation of lipids in the body is mainly achieved
through lipoproteins, a group of protein and lipid emulsions
that vary from 10 to 100 nm in diameter (1). Central in
lipoprotein metabolism are the apolipoproteins. Apolipopro-
teins are essential for lipoprotein formation, transportation,
metabolic reaction, and receptor recognition (1). Structur-
ally, these proteins are composed of similar secondary struc-
tural motifs—amphipathic a-helices and b-sheets, which are
essential for lipid interaction (2,3). However, the tertiary
structure of apolipoproteins and their assembly on lipopro-
tein particles is poorly understood. Computational modeling
remains the primary tool and empirical data are lacking. The
challenge lies in the structural ﬂexibility of apolipoproteins
and the intrinsic heterogeneity associated with lipoprotein
samples, which are often difﬁcult to overcome by biochem-
ical puriﬁcation.
Apolipoprotein B (apoB) is the major protein component
in low-density lipoprotein (LDL), also known as the ‘‘bad
cholesterol,’’ which is directly implicated in atherosclerosis.
ApoB regulates the synthesis of chylomicrons from the small
intestine and very low density lipoproteins, the precursor of
LDL from the liver (4). As one of the largest proteins in hu-
mans, full-length apoB (B100) is composed of 4536 amino
acids and is highly glycosylated (5). The current model of
B100 suggests a ba1-b1-a2-b2-a3 pentapartite superdomain
organization, in which b corresponds to domains rich in am-
phipathic b-sheets, and a corresponds to domains rich in
amphipathic a-helices (3). These amphipathic sequences are
the basic building blocks to achieve lipid interaction in lipo-
protein particles. When the protein is separated from its lipid
components, apoB is no longer soluble as a monomer (6).
The structure of apoB in LDL has been studied at several
labs and models at .20 A˚ resolution have been proposed
using cryo-electron microscopy and crystallography (7–10).
Based on these low resolution models of LDL, apoB ap-
pears to form belts that wrap around on the surface of an
LDL particle. Electron microscopic studies also indicate that
the N-terminal region of apoB protrudes away from the
LDL particle, suggesting a globular fold (7,9). Indeed, the
N-terminal 20.5% of apoB is homologous to lipovitellin, a
globular protein found in the egg yokes of lamprey, whose
atomic structure has been determined by crystallography
(11–13). Based on the structure of lipovitellin, several labs,
including ours, have proposed comparative models of the
N-terminal region of apoB (11,14,15) (Fig. 1, a and b). We
further tested the homology model of B17 using limited
proteolysis, chemical cross-linking, and circular dichroism.
These studies showed that most empirically determined do-
main boundaries, domain interactions, and secondary struc-
tures are consistent with the lipovitellin-based B17 model (15).
Although the N-terminal region of apoB may not directly
interact with lipids in LDL, it clearly plays an indispensable
role in the assembly of an apoB-containing lipoprotein.
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Through the expression of C-terminally truncated apoB
constructs, it has been demonstrated that the N-terminal
19.5 or 22% of apoB was sufﬁcient to support the secretion
of spherical lipoprotein particles (16,17). Moreover, the
N-terminal b-barrel and a-helical domains of apoB are the
only identiﬁed locations responsible for the interaction with
microsomal triglyceride transfer protein (MTP), a critical
chaperone for apoB assembly in the endoplasmic reticulum
(11,18). Interestingly, as a protein of 894 amino acids, MTP
shares homology with lipovitellin and B17 (11). Although
the exact role of MTP in vivo is not yet clear, this chaperone
is critical for efﬁcient lipoprotein assembly. In vitro, MTP
transfers neutral lipids from donor vesicles to acceptor ves-
icles, which suggests its potential lipid shuttling function
during the lipidation of apoB (19). Besides its shuttling ca-
pability for neutral lipids, MTP has been also suggested to
play structural roles to assist the stabilization of lipoprotein
particles during the synthesis of the nascent apoB polypep-
tide (20). In addition, studies by Rava et al. (21) suggested
that the phospholipid transferring activity of MTP is sufﬁ-
cient to support lipoprotein assembly and secretion.
The N-terminal region of apoB contains intrinsic lipid re-
modeling activities, although to what extent these activities
are involved in lipoprotein assembly has not been estab-
lished. It has been demonstrated that B17 binds phosphati-
dylcholine vesicles in vitro and has the capability to convert
dimyristoylphosphatidylcholine (DMPC)multilamellar vesicles
into discoidal particles (22,23). Using DMPC as a model
lipid, we have shown that, in B17, the DMPC binding se-
quences largely reside in the N-terminal half of the a-helical
(B6.4-10) and C-sheet (B13-17) domains, but not in the
N-terminal b-barrel (B5.9) or the C-terminal half of the
a-helical domain (B9-13) (Fig. 1, a and c) (24). Although
the reconstituted particles obtained in vitro do not exist in
vivo, the structure of these reconstituted particles may
provide important insights into the biophysical properties
and potential conformation of apoB domains during the
initiation of lipoprotein assembly. In this article, we continue
our study of the phospholipid-binding regions in B17 and
characterize the structure of B6.4-17 in reconstituted lipo-
protein particles using a novel strategy that incorporates
spectroscopic methods, limited proteolysis, and scanning
transmission electron microscopy (STEM). These methods
allow us to propose an in vitro working model of the con-
formation of B6.4-17 in a reconstituted DMPC particle.
MATERIALS AND METHODS
Protein cloning, expression, and puriﬁcation
Protein constructs, including B6.4-10 (residues 292–469), B6.4-13 (residues
292–593), B6.4-17 (residues 292–782), and B9-13 (residues 430–593), were
cloned into the pET24a vector (EMD Chemicals, San Diego, CA) and
expressed in BL21 DE3 Escherichia coli cells using standard protocols.
Each construct has a 6-His tag on its C-terminus. Cells were grown at 37C
to an optical density of 0.6–0.8 at 600 nm in Luria broth supplemented with
kanamycin (34 mg/ml). Expression was then induced with 1 mM isopropyl-
b-D-thiogalactopyranoside and the cells were grown for an additional 3 h.
Cell pellets were lysed with 1 mg/ml lysozyme at room temperature for 30
min and then sonicated with a probe sonicator (Branson, Danbury, CT). The
protein-containing inclusion bodies were dissolved in 8 M urea after
washing with 1% Triton X-100 and 1 M Urea. Soluble proteins were loaded
on a Ni-NTA Sepharose column (Qiagen, Valencia, CA) and eluted with 250
mM imidazole and 6 M guanidine hydrochloride (GuHCl). Protein refolding
was achieved by slowly adding concentrated protein stocks in 6 M GuHCl
into a refolding buffer containing 50 mM tris(hydroxmethy)aminomethane
(Tris), 800 mM arginine, 10 mM reduced glutathione, 2 mM oxidized
glutathione, and 0.02% sodium azide at pH 8.0. Protein at 1–2 mM in the
refolding buffer was incubated at 4C overnight and then dialyzed
extensively against 10 mM Tris and 150 mM sodium chloride, pH 7.5
(TS buffer). The ﬁnal protein volume and concentration were adjusted using
an Amicon Ultra concentrating apparatus (Millipore, Billerica, MA) and the
protein concentration was determined by UV absorbance at 280 nm (25).
DMPC vesicle preparation and reconstituted
particle formation
To prepare multilamellar 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)
suspensions, 10 mg DMPC (Avanti Polar Lipids, Alabaster, AL) in chloro-
form was transferred to a round bottom ﬂask and connected to a rotary evap-
orator (Buchi, New Castle, DE) to form a uniform DMPC thin layer, which
was then placed under vacuum for 1 h to remove residual chloroform. The
lipid was hydrated with 5 ml TS buffer and gently agitated with small glass
beads at room temperature to form multilamellar DMPC suspensions. To
form reconstituted lipoprotein particles, B6.4-17 at 1 mg/ml was mixed with
the DMPC suspension at the desired ratio in TS buffer and incubated at 24C
for at least 16 h.
FIGURE 1 Homology model of B17. (a) Comparison of domain struc-
tures of lipovitellin (LV) and apoB. Only the N-terminal 20% of apoB is
colored by proposed domains. b-barrel domain, green; a-helical domain,
cyan; C-sheet, red; A-sheet, dark blue; missing regions in the structure of
LV, white. A domain diagram of B17 has been colored by phospholipid
remodeling efﬁciencies. Lighter color corresponds to more efﬁcient phos-
pholipid remodeling activities as determined previously (24). (b) Ribbon
representation of the B17 model colored by domain as in panel a. (c) Ribbon
representation of B17 colored by the phospholipid remodeling sequences as
in panel a.
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Size exclusion chromatography analysis
B6.4-17 or B6.4-17/DMPC particles were prepared at 0.5–1 mg/ml protein
concentration at the speciﬁed L/P ratios and then injected onto a Superdex
GL-200 column (GE HealthCare, Piscataway, NJ). The column was eluted
with TS buffer at 0.5 ml/min and 4C and the elution was monitored by
absorbance at 280 nm.
Circular dichroism analysis
Circular dichroism (CD) data were collected on an AVIV 215 instrument
(AVIV, Lakewood, NJ). Protein or B6.4-17/DMPC samples at 1–2 mM
(protein concentration) were dialyzed against 5 mM potassium phosphate at
pH 7.5 before the experiment. The exact protein concentration was
determined by absorbance at 280 nm immediately before the wavelength
scan. Each reported wavelength scan was an average of four scans taken in a
1 mm cuvette with a 5-s averaging time at every nm. CD scans for the buffer
and cuvette were measured right before the data collection for background
correction. For chemical denaturation experiments, protein samples at 0.1–
0.2 mM were prepared in 5 mM potassium phosphate, pH 7.5. Protein
unfolding was achieved using an AVIV titration accessory by the addition of
the same concentration of protein in 7 M GuHCl, pH 7.5, in 0.1 M steps into
2.0 ml native protein solution in a 1 cm cuvette. The sample volume was
maintained constant throughout the titration, and protein unfolding was
monitored at 222 nm at 25C. After each injection of denaturant, the sample
was stirred for 3 min, equilibrated for 20 s and the data were collected with
an averaging time of 20 s. Since most of the unfolding curves do not exhibit
typical two-state transitions, the percentage unfolding at each GuHCl con-
centration (%Unfolded [x]) was calculated using a modiﬁed equation:
%Unfolded½x ¼ ðu½0  u½xÞ=u½03100;
in which u[0] is the CD signal in the absence of GuHCl. This modiﬁcation
allows the comparison of curves without arbitrary determination of the folded
and unfolded baselines. For comparison, a conversion using the ﬁrst 10 data
points as the folded baseline and the CD signal at 6 M GuHCl concentration
as the unfolded reference was used to calculate the inset plot in Fig. 3 c.
Limited proteolysis, HPLC, and mass
spec analysis
Trypsin from bovine pancreas (Sigma, TPCK-treated; St. Louis, MO) was
freshly prepared at 1mg/ml in 1mMHCl and added to 250ml of 1mg/mlB6.4-
17 or B6.4-17/DMPC complexes in TS buffer to produce the ﬁnal trypsin to
protein ratio of 1:1000 (w/w). The mixtures were incubated at room tempera-
ture for 15 min. The proteolytic digestion was terminated by the addition of
2-mercaptoethanol to a ﬁnal concentration of 10 mM and acidiﬁcation with
glacial acetic acid to a ﬁnal concentration of 5%.Digestion productswere either
analyzed by SDS-tricine (26) gels or high performance liquid chromatography
(HPLC) on an analytical C4 reverse phase column (Grace Vydac, Columbia,
MD). The columnwas eluted at 1ml/minwith a 1%/min gradient fromwater to
90% acetonitrile with 0.1% triﬂuoroacetic acid throughout the gradient and
monitored at 220 nm. Samples for N-terminal sequencing were puriﬁed either
from SDS-tricine gels or by HPLC. Peak fractions fromHPLCwere analyzed
with matrix-assisted laser desorption ionization time-of-ﬂight mass spec-
trometry to determine the molecular weight of each fragment at the Molecular
Biology Core Facility of the Dana Farber Cancer Institute.
Ni-NTA-Nanogold labeling
Ni-NTA-Nanogold (Nanoprobes, Yaphank, NY) at 10mMwas incubatedwith
3.3 mM (protein concentration) reconstituted B6.4-17/DMPC particles for 15
min at room temperature. The mixture was then loaded on a Superdex GL-200
column to remove excess protein andNi-NTA-Nanogold from the reconstituted
particles. The column was eluted with TS buffer at 0.5 ml/min at 4C.
Negative stain electron microscopy
For negative stain electron microscopy, reconstituted B6.4-17/DMPC
particles (4 ml) at 0.1–0.5 mg/ml (protein concentration) were loaded on a
carbon-coated and glow-discharged copper grid (SPI Supplies, West
Chester, PA) for 1 min, washed with 10 drops of distilled water and stained
with 1% sodium phosphotungstate, pH 7.5 or Nanovan (Nanoprobes,
Yaphank, NY) for 30 s (27). All samples were imaged on a Philips CM12
transmission electron microscope (FEI Company, Hillsboro, OR) operated at
120 kV with a LaB6 ﬁlament and recorded on SO-163 EM (Kodak, New
Haven, CT) ﬁlms at 45,0003 magniﬁcations under minimal electron dose
conditions. The ﬁlm was processed with undiluted Kodak D-19 developer
for 12 min and Kodak rapid ﬁxer for 5 min. Electron micrographs were
digitized on a Creo IQ Smart2 Scanner (Kodak, Rochester, NY) at 1270 dpi.
Sample preparation and STEM imaging
Grids for the STEM were prepared by the wet ﬁlm technique as described
previously (28,29). Brieﬂy, 2.3 mm titanium grids, coated with a thick holey
ﬁlm, were placed on a ﬂoating thin (2–3 nm) carbon ﬁlm prepared by ultra-
high vacuum evaporation onto freshly cleaved rock salt. Both the sample
and the tobacco mosaic virus, an internal standard, were allowed to adsorb to
the carbon ﬁlm for 1 min. The grids were washed extensively, ending with a
volatile buffer, blotted to a very thin layer of liquid and plunged into liquid
nitrogen slush. They were later transferred to an ion-pumped freeze-drier,
freeze-dried overnight, and transferred under vacuum to the STEM.
The STEM was operated in a dark-ﬁeld mode. The scattered electrons
were collected in two annular detectors from each pixel and the number of
scattered electrons (in each pixel) was directly proportional to the mass
thickness in that pixel. By summing the scattered electrons over a particle
and subtracting the background from the thin carbon ﬁlm, the mass of the
particle can be determined. B6.4-17/DMPC particles were imaged by the
STEM at the Brookhaven National Laboratory, which is described in more
detail at http://www.biology.bnl.gov/stem/stem.html.
Analysis of STEM images
A total of 1382 well-dispersed particles were manually picked from 72
independent STEM images using PCMass28 (30) and were categorized into
1 of the 16 geometrical groups as deﬁned in Fig. 6. The mass of each particle
was determined using two background correction methods available in
PCMass28: the entire image background and the local background. Two
types of particles were excluded in the statistical analysis: 1), particles that
did not fall into any of the 16 geometrical groups; and 2), particles with
molecular weight differences .20% using the two background correction
methods. A total of 1315 particles met these two criteria and were used in
the statistical analysis. Statistical analysis was performed in Origin 7.5
(OriginLab, Northampton, MA).
Protein modeling and graphics presentation
The homology model of B17 was generated with MODELLER as described
previously (15).Molecular imageswere generated inMOLMOL(31). Pov-Ray
3.6 (www.povray.org) was used to generate the cylinder-ribbon representation
of the proposed B6.4-17 tertiary folding in a reconstituted DMPC particle. The
lipid core and each B6.4-17 domains were kept approximately to scale.
RESULTS
Preparation of B6.4-17 and B6.4-17/DMPC
reconstituted particles
B6.4-17 contains all phospholipid remodeling sequences
within B17, including the proposed a-helical and C-sheet
domains (Fig. 1, a and b) (24). This construct encompasses
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the central regions in the corresponding lipovitellin structure,
but lacks the N-terminal b-barrel domain (B5.9) that is
difﬁcult to refold in high yield and does not interact with
lipids (15). In lipovitellin, the a-helical domain serves as a
clamp that maintains the relative position of the C-sheet
and the A-sheet (12,13). B6.4-17 forms inclusion bodies
when expressed in E. coli, but it can be routinely refolded
to a monomeric state using the method previously described
(15). B6.4-17 clears turbid DMPCmultilamellar vesicles and
forms reconstituted lipoprotein particles in vitro (24). These
DMPC-reconstituted particles can be separated from lipid-
free proteins using size exclusion chromatography (Fig. 2 a).
Similar to the behavior of apoA-I, the size of the reconsti-
tuted particles correlates with the initial lipid-to-protein ratio
(L/P) (32). Higher L/P ratios gives rise to larger particles and
the reconstituted particle peak elutes earlier (Fig. 2 a). When
the peak fractions from the size exclusion column are ana-
lyzed with negative stain electron microscopy, the images
of these particles are reminiscent of the reconstituted high
density lipoprotein (HDL) particles using apolipoprotein A-I
(apoA-I) (Fig. 2, b and c) (32,33). We also found that when
the protein is in excess (L/P , 1.25, wt/wt), the B6.4-17/
DMPC complex reaches a minimal size (24). This observation
suggests that a minimal, ﬁxed amount of DMPC is required
to form a stable complex in excess protein. Because the size
and composition of these minimal-sized particles are the most
uniform and are not inﬂuenced by slight differences in protein
and lipid concentrations, they are the focus of this study.
Characterization of protein conformation by
circular dichroism spectroscopy
Both homologous modeling and biophysical studies suggest
that B6.4-13 is a largely a-helical domain (15). The a-helical
domain in lipovitellin contains an extensively hydrophobic
interface between the two layers of a-helices, which main-
tains the integrity of the helix bundle (Fig. 1 b). Yet, we no-
ticed that the N-terminal half (B6.4-10) and C-terminal half
(B9-13) of the a-helical domain behave differently when
they are exposed to phospholipid bilayers, suggesting po-
tential differences in their biophysical properties (24). To
compare these two potential subdomains within B6.4-13, the
protein conformation of B6.4-10 and B9-13 were charac-
terized using circular dichroism (CD). Both truncated con-
structs give typical a-helical spectra, with minima at 222 nm
and 209 nm. The mean residue a-helical content of either
truncated construct is 25–30% less than that of B6.4-13 by an
approximate calculation based on the ellipticity at 222 nm
(Fig. 3 a). Despite the similar overall secondary structure be-
tween B6.4-10 and B9-13, guanidine hydrochloride (GuHCl)
denaturation monitored by CD reveals a signiﬁcant differ-
ence in their chemical stability. The unfolding of B6.4-10
(left facing triangles) with increasing GuHCl concentration
is almost linear, suggesting a molten globule conformation
that lacks a ﬁxed hydrophobic core (Fig. 3 b). In contrast,
B9-13 (right facing triangles) has a clear transition point at
2.1 M GuHCl, consistent with a cooperative protein unfolding
model. The unfolding curve of B6.4-13 (diamonds) appears
to reﬂect the combined unfolding of both subdomains.
The potential conformational changes of B6.4-17 upon the
formation of reconstituted lipoproteins are examined by
CD as well. The far-UV CD wavelength scan of B6.4-17
exhibits the typical characteristics of a-helical proteins. The
incorporation of B6.4-17 into a DMPC complex does not
change the overall shape of the far-UV CD spectrum, sug-
gesting that no large changes in the protein secondary struc-
ture have occurred (24). The protein tertiary structure was
probed by GuHCl denaturation and monitored by CD at 222
nm, which primarily tracks changes in a-helical structures.
B6.4-17 in DMPC complexes appears to exhibit unfolding
curves comparable to the lipid-free protein (Fig. 3 c), but the
extent of unfolding is ;10% less than that of the lipid-free
protein. This observation suggests that the binding to DMPC
may stabilize slightly more a-helical segments, but does not
cause dramatic changes in the unfolding cooperativity. In-
deed, when both curves are ﬁtted by their folded based line,
FIGURE 2 B6.4-17 forms reconstituted particles with DMPC. (a) Size
exclusion chromatography of reconstituted B6.4-17/DMPC particles. Thin
shaded line, lipid-free B6.4-17; thick shaded line, B6.4-17/DMPC complex
at 1:1 L/P weight ratio; thick solid line, B6.4-17/DMPC complex at 4:1 L/P
weight ratio; dotted shaded line, B6.4-17/DMPC complex at 0.8:1 L/P
weight ratio with Ni-NTA-Nanogold labels (AU); B6.4-17/DMPC complex
at 4:1 L/P weight ratio with Ni-NTA-Nanogold labels. (b,c) Negative stain
electron microscopic images of reconstituted B6.4-17/DMPC particles at 1:1
L/P weight ratio (b) and 4:1 L/P weight ratio (c). The magniﬁcation bar cor-
responds to 50 nm in both images.
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the shapes of the transitions are identical (inset in Fig. 3 c).
The similar shape of these two curves suggests that DMPC
binding does not change the unfolding cooperativity of B6.4-
17, which is largely achieved by the tertiary structure and the
formation of hydrophobic cores.
Conformational changes probed by
limited proteolysis
Protease susceptibility is an indication of unstructured pro-
tein sequences, as folded structure is usually protected from
proteolytic degradation. Therefore, a comparison of limited
proteolysis patterns in lipid-free and lipid-bound forms serves
as a sensitive tool in identifying unstructured regions or lipid-
interacting sites. Both lipid-free B6.4-17 and the B6.4-17/
DMPC complex were incubated with trypsin (1000:1 wt/wt,
respectively) for 15 min, and their proteolysis patterns were
compared (Fig. 4). Similar fragments (1a and 2a, 2b) at;35
kDa were observed for both samples. In the proteolysis of
the B6.4-17/DMPC complex, an additional fragment at ;20
kDa (2c) and a less signiﬁcant fragment at a smaller mo-
lecular weight (2d) were observed. In contrast, no signiﬁcant
fragment of a similar size was observed in lipid-free B6.4-17.
To identify these fragments, proteolytic products were
puriﬁed on a C4 reverse phase column and subjected to
N-terminal sequencing and mass spectrometry analysis. A
common cleavage after Lys614 is observed for both lipid-free
and DMPC-bound B6.4-17 (Table 1). This cleavage, located
in the middle of the ﬁrst proposed b-strand in the C-sheet,
was also observed in the trypsin digestion of B17 as pre-
viously reported (15). Fragments 1a and 2a correspond to
the a-helical domain and fragment 2b corresponds to the
a-helical domain missing 15 (or 16) residues at the N-terminus
and 10 (or 9) residues at the C-terminus. Interestingly, the
incorporation of B6.4-17 into DMPC particles protects the
protein from trypsin cleavage in the C-sheet, as fragment 2c
and 2d are almost absent in the digestion of lipid-free B6.4-
17. Fragment 2c is indeed the proposed C-sheet domain after
the cleavage at Lys614, while fragment 2d is missing the
N-terminal 14 amino acids from fragment 2c (Table 1). The
protection of the C-sheet in the digestion of the DMPC-
bound B6.4-17 indicates that this domain is stabilized against
proteolysis by DMPC probably through direct involvement
in lipid binding.
Ni-NTA-Nanogold labeling of the reconstituted
B6.4-17/DMPC particles
Previously, we have described the morphology of the recon-
stituted B6.4-17/DMPC particles imaged by negative stain
electron microscopy (EM) (24). The contrast in a negative
stain image comes primarily from the stain, thus it fails to
differentiate the protein and lipid moieties. Based on the
observation of the plate- and rod-shaped morphologies of
B6.4-17/DMPC complexes, a discoidal DMPC complex
model has been proposed (Fig. 2, b and c) (24). However,
FIGURE 3 Circular dichroism studies of B6.4-17 and its subdomains. (a)
CD wavelength scans of B6.4-13 ()), B6.4-10 (9), and B9-13 (8).
Samples contained;5 mM protein in 5 mM potassium phosphate at pH 7.5,
in a 1 mm cuvette at 25C. Four scans with an averaging time of 5 s at every
nm were collected and the average data are reported. (b) GuHCl titration of
B6.4-13 ()), B6.4-10 (9), and B9-13 (8). (c) GuHCl titration of B6.4-17
(n) and B6.4-17/DMPC complex (:) at 1.2:1 L/P ratio. Native proteins in a
1 cm cuvette were titrated by the protein at the same concentration in 7 M
GuHCl at 0.1 M per step at 25C. After each injection of the denaturant, the
sample was stirred for 3 min and the CD signal at 222 nm was averaged for
20 s. The raw CD data were converted to percentage unfolded by calculating
the ratio between each data point and the CD signal at 0 M GuHCl as
described in Materials and Methods. In the inset ﬁgure, the percentage
unfolded curve was calculated by applying a folded baseline using the ﬁrst
10 data points and using the CD signal at 6 M GuHCl as the unfolded
reference.
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an alternative vesicle interpretation is difﬁcult to exclude
since the staining process inevitably introduces artifacts and
could potentially collapse fragile vesicles. Furthermore,
although only a 15% standard deviation is observed in the
average diameter of the minimal-sized particles, the negative
stain method cannot be used to determine variations in
protein/lipid stoichiometry or the geometry of proteins on
individual particles.
To overcome these problems, we used a Ni-NTA-Nanogold
probe to label the protein component of the reconstituted
lipoprotein particles. Ni-NTA-Nanogold contains a 1.8 nm
gold particle with multiple nickel-nitrilotriacetic acid (Ni-
NTA) groups on the surface (34). This probe speciﬁcally
labels the C-terminus of B6.4-17 through its 6-His tag and
allows the direct localization of each individual protein mol-
ecule. To generate gold-labeled particles, a threefold molar
excess of nanogold was incubated with the reconstituted
DMPC complexes and the unbound nanogold was removed by
puriﬁcation on a size exclusion column. Three peaks were
observed, corresponding to the excess nanogold, nanogold-
labeled complex and nanogold-labeled protein (Fig. 2 a).
The nanogold labeled proteins elute earlier than unlabeled
proteins on a size exclusion column as expected due to the
increase in mass from the large gold particle.
Imaging of nanogold labeled particles using negative stain
EM is technically challenging. A 1.8-nm gold particle is
slightly larger than the grainy noise on the electron micro-
graph (Fig. 5 a). Gold enhancement may increase the visi-
bility of the nanogold, but it also lowers the homogeneity of
the nanogold particles because the solvent accessibility of
each nanogold can be different, depending on how the DMPC
FIGURE 4 Limited proteolysis of B6.4-17 and B6.4-17/DMPC particles.
Lipid-free B6.4-17 and B6.4-17/DMPC complexes (1.2:1 wt/wt L/P ratio)
were prepared at 1 mg/ml protein concentration in 20 mM Tris-HCl and 150
mM sodium chloride, pH 7.5. Freshly prepared Trypsin in 1 mM HCl was
added to a protein to trypsin ratio of 1000:1 (wt/wt) and incubated for 15 min
at room temperature. The digestion was stopped by the addition of 10 mM
b-mercaptoethanol and acetic acid to 5%. Lane 1, protein standards; lane 2,
B6.4-17 before digestion; lane 3, B6.4-17 after digestion; lane 4, B6.4-17/
DMPC after digestion. The major proteolytic products are labeled to the left
of the gel and are identiﬁed in Table 1.
TABLE 1 Identiﬁcation of proteolytic digest products
Fragment*
N-terminal
sequence
Experimental
MW
Predicted
fragment
Calculated
MWy
Calc. vs. Exp.
MW error
1a PKQAE 36851.5 292–614 36783.5 0.18%
2a PKQAE 36820.3 292–614 36783.5 0.10%
35558.8 292–605 35583.1 0.07%
2b KLTIS 33767.0 307–604 33777.0 0.03%
LTISE 308–605 0.03%
2c SVSLP 19240.9 615–782 19219.0y 0.11%
2d IEGNL 17985.2 628–782 17965.6y 0.11%
*The identity of each fragment is deﬁned in Fig. 4.
yThe calculated molecular weight includes six histidines at the C-terminus
of the protein.
FIGURE 5 Imaging of the reconstituted B6.4-17/DMPC particles. (a)
Negative stain image of reconstituted DMPC particles labeled with Ni-NTA-
Nanogold. (b) Negative stain image of reconstituted DMPC particles labeled
with Ni-NTA-Nanogold after gold enhancement. Ni-NTA-Nanogold was
added to a 3:1 molar ratio to the protein/lipid mixture before the preparation
of EM-grids. Protein samples were stained by Nanovan and gold enhance-
ment was performed according to the protocol from Nanoprobes. The
magniﬁcation bar corresponds to 20 nm for both images. White triangles
point to gold particles. (c) STEM image of reconstituted B6.4-17/DMPC
particles at 0.8:1 L/P weight ratios. The reconstituted particles had been
puriﬁed on a Superdex GL 200 column (Fig. 2). Tobacco mosaic virus was
used as an internal standard as shown in the image. The magniﬁcation bar
corresponds to 20 nm. Six reconstituted particles (i–vi) are shown in en-
larged views (36 3 36 nm) on the right.
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particle is oriented on the grid (Fig. 5 b). However, optimal
imaging can be achieved using scanning transmission elec-
tron microscopy (STEM).
STEM does not require heavy metal stain; image contrast
is solely achieved from the difference in the sample density
(35). Because of the much higher density of gold, the nano-
gold probe is easily visible without enhancement (Fig. 5 c).
After the analysis of over 1300 particles prepared at 0.8:1
L/P (wt/wt) ratio (excess protein) and 500 particles prepared
4:1 L/P (wt/wt) ratio (excess lipid), we found that the nano-
gold labels appear exclusively on the circumference of the
particle, when the particle is in a ‘‘plate’’ view. Notably, fewer
particles in rod views are observed and no rouleaux (stacks
of particles) are spotted using STEM, which suggests that the
formation of rouleaux may be promoted by the heavy metal
stain. This observation provides direct support for the discoi-
dal model of the reconstituted particle, in which the protein
wraps around a DMPC bilayer core and covers the circum-
ferential hydrocarbon chains. Otherwise, it would be expected
that many nanogold labels would be seen on the particle if
the reconstituted lipoprotein adopts a vesicular structure and
the protein randomly docks in the phospholipid bilayer.
Assembly of proteins in a reconstituted
DMPC complex
Ni-NTA-Nanogold labeling and STEM imaging provide a
much more informative image of the reconstituted DMPC
complex. Although we found that the distribution of nano-
gold on the lipoprotein particle is not uniform, certain tenden-
cies are observed. For instance, ﬁve representative groups of
particles are illustrated in Fig. 5 c. Both particles i and ii have
three nanogold labels, yet the nanogold layout in particle
i adopts a threefold symmetry (C3 symmetry); while particle
ii appears nonsymmetrical, probably missing one nanogold
in a fourfold symmetrical (C4 symmetry), which is shown
in particle vi. Particles iii–v all have two gold labels. Yet,
particle v differs from particles iii and iv in the way these two
nanogold labels are positioned. Since the nanogold attaches
to the 6-His at the protein C-terminus, particles iii and ivmay
adopt a head-to-tail protein assembly, while particle v may
adopt a tail-to-tail assembly.
We manually picked;1400 particles prepared at 0.8:1 L/P
(wt/wt) ratio, analyzed ;1300 of them, and grouped them
based on the number of nanogold labels observed on each
particle. The excluded particles either had high error in their
molecular weight, or did not did correspond to one of the
16 geometrical groups shown in Fig. 6. Almost half of the
particles have two gold labels and one third of the particles
have three gold labels (Fig. 6 a). An accumulative plot sug-
gests maximum labeling occurs at three nanogolds, since it
is where the curve reaches its statistical plateau (Fig. 6 b).
Based on the geometry of the nanogold labels, these particles
were further classiﬁed into 16 geometrical groups, which we
found were sufﬁcient to characterize most of the reconsti-
tuted particles imaged by STEM (Fig. 6 c). A few larger
particles that lack deﬁnitive morphology were excluded in
our analysis, and we speculate that they were fused vesicles.
The statistics indicate that the two nanogolds in a C2
symmetry (Fig. 6 c, group #5) occurs most frequently among
the 16 geometrical groups. Following that are the groups of
two nanogolds in a nonsymmetrical assembly (#7), three
nanogolds with C3 symmetry (#9), and three nanogolds in a
nonsymmetrical assembly (#10). It should be noted that in-
complete nanogold labeling is possible in our preparation.
Therefore, some particles in group #7 may in fact have three
proteins in a C3 symmetry. Similarly, some particles in group
#10 may have four proteins in a C4 symmetry. Since incom-
plete labeling should occur equally in all geometrical groups,
the fact that only a few particles have a single nanogold label
suggests that labeling is close to complete. Based on the ratio
between particles with a single gold label and particles with
two gold labels, we believe that incomplete labeling is
;10% in our preparation (Fig. 6, a).
Size of the reconstituted DMPC particles
Since the image intensity is a measure of sample density,
STEM provides a direct measurement of the molecular weight
for each reconstituted particle. The average molecular weight
FIGURE 6 Categories of nanogold-labeled particles. (a) Histogram of the
number of nanogold on each particle. A total of 1315 particles were analyzed,
and are categorized based on the number of nanogolds attached on each
particle. (b) Accumulated plot of the nanogold count. Each data point rep-
resents the sum of the number of particles in this group plus the accumulated
number of particles in the previous groups. (c) Histogram of the 16 geo-
metrical groups. Nanogold-labeled particles were categorized into 16 geo-
metrical groups as indicated at the bottom of the histogram. The number of
particles counted in each group was plotted with shaded bars.
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of a Ni-NTA-Nanogold is 25.76 9.0 kDa, as measured from
207 nanogolds in 10 independent images. The molecular
weight of each reconstituted particle is calculated from the
measured molecular weight excluding the molecular weight
of the nanogold, i.e., the number of nanogolds times 25.7 kDa.
The average molecular weight can be compared among
particles with different numbers of observed nanogold labels
(Fig. 7 a). A statistically signiﬁcant increase (p , 0.01) in
molecular weight is observed with an increasing number of
nanogold labels from 2 to 4, the three groups that constitute
93% of all analyzed particles. Since the number of nanogolds
corresponds to the number of proteins per particle, this in-
crease in molecular weight is expected. Rather surprisingly,
the increase is smaller than 56 kDa, the molecular weight of
B6.4-17. The increase of the average molecular weight for
particles with two nanogold labels to three nanogold labels is
28 kDa and from three to four is 39 kDa (Fig. 7 a). In other
words, current data do not suggest a correlation between the
increase in the size of the DMPC core and the increase of the
number of proteins on the particle. Rather, the addition of
the third protein results in a particle with fewer lipid molecules.
Subgroups #5 (C2 symmetry) and #9 (C3 symmetry) rep-
resent the most commonly observed geometrical orientations
(Fig. 6 c). The molecular weight distributions of the recon-
stituted particles in these two subgroups indicate a slight, but
discernable increase in the molecular weight (Fig. 7, b and c).
The average molecular weight of particles in the C2 and C3
symmetry is 2636 77 kDa and 2896 81 kDa, respectively.
Based on these values, the average number of protein and
DMPC molecules in each particle is: C2, two proteins and
222 DMPCmolecules; and C3, three proteins and 181 DMPC
molecules. These values correspond to the L/P weight ratios
of 1.34 and 0.72. Applying similar calculations on all geo-
metric groups, the average L/P weight ratio for all 1315
particles is 1.17. Notably, when using previously described
biochemical methods to measure the protein and phospho-
lipid concentrations separately, we obtain an L/P weight ratio
of 1.24 for the puriﬁed minimal-sized B6.4-17/DMPC par-
ticles (24). Therefore, the measurements made from the
single particle STEM analysis is consistent with those ob-
tained from gross biochemical analysis. Moreover, this single-
particle-based analysis presents geometrical and statistical
information that is unavailable in gross biochemical analysis.
DISCUSSION
After three decades of extensive study, the mechanism that
underlies the formation of lipoproteins remains elusive. The
difﬁculty in obtaining high resolution structures for apoli-
poproteins, especially in the lipid-bound form, prevents our
understanding of this vital process at a molecular level. Pre-
sumably, one of the major difﬁculties derives from the con-
formational ﬂexibilities of apolipoproteins, which may be
critical for their physiological functions, but imposes enor-
mous technical complications in structural studies. A structur-
ally homogenous sample is the prerequisite for most structural
methods, including crystallography, NMR, and electron
microscopic reconstruction. On the other hand, apolipopro-
teins are structurally simpler, because they often have
characteristic secondary structural elements, i.e., amphipathic
a-helices or b-sheets. Computational modeling incorporated
FIGURE 7 Molecular weights of nanogold-labeled particles. (a) The av-
erage molecular weight of the reconstituted particle when different numbers
of nanogold labels are present. The molecular weight of each reconstituted
particle was measured with PCMass28 (30). The mass that corresponds to
the nanogold was excluded during statistical analysis. The error bar cor-
responds to the standard deviation of the calculated molecular weight at each
stoichiometry. The number of particles in each group was labeled on the top
of each dataset. Datasets with an asterisk have a P-value,0.01 among each
other, as calculated by analysis of variance in Origin 7.5 (Microcal). (b,c)
The frequency of occurrence of the molecular weight for particles with a C2
symmetry (b) or a C3 symmetry (c).
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with constraints obtained from biophysical methods and
direct imaging can be a valid strategy to obtain structural
insights into the function of these proteins.
Here we introduce a novel approach to obtain such struc-
tural constraints for the N-terminal domain of apoB in a
reconstituted lipoprotein particle. Direct imaging using cryo-
electron microscopy and pattern characterization has been
successfully utilized by van Antwerpen and co-workers to
unveil the heterogeneity in serum derived lipoproteins (36).
Our method is based on a similar strategy, but involves the
use of Ni-NTA-Nanogold labeling and scanning transmis-
sion electron microscopy (STEM). This method allows an
easier and more precise evaluation of individual particles in a
sample that is heterogeneous, but not random. The geomet-
rical assembly and molecular weight information obtained
from this study reveals the range of the heterogeneity of these
particles and provides insights into the possible structural
basis behind such heterogeneity. This information is not ac-
cessible with average-based biochemical analyses of these
particles. It should be noted that such nonrandom heteroge-
neity may not only exist in the B6.4-17/DMPC complex, but
also among other naturally present lipoproteins or lipopro-
tein intermediates. Behind these heterogeneous observations
lie the biophysical properties of the apolipoproteins, their
domain structures and interactions.
Combined with limited proteolysis, biophysical charac-
terization and comparative modeling, we propose a working
model of B6.4-17 in a reconstituted DMPC complex. In this
model, three structural elements in B6.4-17 are involved in
DMPC binding: the N-terminal half of the a-helical domain,
the b-sheets in the C-sheet domain, and two proposed am-
phipathic a-helices in the middle of the C-sheet domain that
are missing in the lipovitellin-based model (Fig. 8, a and b).
These three structural elements shield the exposed hydro-
carbon chains on the circumference of the DMPC bilayer and
stabilize the particle (Fig. 8, b and c).
The N-terminal half of the a-helical domain contains the
phospholipid remodeling activity, while the C-terminal half
does not (24). When the protein binds a phospholipid bilayer,
some structural adjustments in N-terminal subdomain may
occur. Such adjustment may involve a hinge motion in the
middle of the a-helical domain. Some opening of the a-helical
bundles can contribute to the change of the orientation of the
N-terminal subdomain (green) compared to its position in
the lipovitellin-based model (Fig. 8 c). This hypothesis is in
agreement with the molten globule nature of this subdomain
as identiﬁed by circular dichroism. Moreover, the limited
proteolysis study also identiﬁed small changes of the trypsin
accessibility in the very N-terminus of B6.4-17.
The C-sheet domain (B13-17), particularly its N-terminal
half (B13-15), has a strong phospholipid binding activity
(24). Furthermore, the protection of a fragment correspond-
ing to the predicted C-sheet is signiﬁcantly enhanced in the
trypsin digestion of B6.4-17/DMPC particles, also indicating
that the C-sheet region in B6.4-17 is directly involved in
DMPC binding. However, it should be mentioned that the
identiﬁed trypsin cleavage sites (Lys614 and Lys627) in the
C-sheet domain are both located in the middle of the pre-
dicted b-sheets in the B17 model (Table 1), which suggests
potential inaccuracies in the current homology model.
CD measurements of the truncated C-sheet (B13-17)
suggest ;20% b-sheet content and ;30% a-helical content
(15). Therefore, the term ‘‘C-sheet’’ may not accurately re-
ﬂect the structure of this domain. Notably, a segment of 64
amino acids (B15.4-16.4) cannot be modeled due to the lack
of electron density in the lipovitellin structure. This segment
contains seven Lys residues, which have better protection
than Lys614 or Lys627 in the trypsin digestion, indicating this
segment may be folded and is likely to interact with DMPC.
Indeed, some sequences in this segment have high scores
for the prediction of being a-helical, which may explain the
observed a-helical content in B13-17. Segrest and co-workers
proposed that this sequence folds into two amphipathic
helices, and stabilizes the lipoprotein particle containing B22
(17,37). Our observation is consistent with this hypothesis.
We propose that these two helices constitute the third DMPC
binding element in B6.4-17.
FIGURE 8 Models of reconstituted B6.4-17/DMPC particles. (a) Domain
diagram of B6.4-17. The N-terminal half of the a-helical domain, green;
C-terminal half of the a-helical domain, cyan; b-sheets in the C-sheet
domain, red; proposed a-helical region in the C-sheet domain missing in the
lipovitellin crystal structure, magenta. (b) Proposed domain interactions in
lipid-bound B6.4-17. The black sphere indicates a nanogold label. (c) A
three-dimensional cartoon of B6.4-17 in a discoidal particle. The orange
disks represent a DMPC bilayer. The lipid core and B6.4-17 domains are
shown approximately to scale. (d–f) Proposed protein assemblies in the
B6.4-17/DMPC particle. (d) Two proteins in a head-to-tail assembly. (e)
Two proteins in a head-to-head assembly. (f) Three proteins in a symmetric
assembly. The expected STEM views are shown on the right corner of each
model.
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Ni-NTA-Nanogold labels and STEM imaging provides
new insights into the molecular assembly of B6.4-17 in a
DMPC particle. First, the exclusive circumferential location
of the nanogold labels directly supports the model that these
reconstituted particles adopt a discoidal shape, with proteins
wrapping around and shielding the hydrophobic acyl chains
of DMPC. Secondly, the reconstituted B6.4-17/DMPC com-
plexes are structurally heterogeneous, and multiple forms of
protein assembly are observed. Most DMPC complexes have
two or three B6.4-17molecules attached. Among these groups,
the geometry of two proteins in a symmetric layout has the
highest frequency. The fact that a symmetric distribution is
more common than nonsymmetrical distributions suggests
that a head-to-tail protein assembly is preferred. Another
unexpected ﬁnding is that the size of the DMPC bilayer does
not increase as more proteins are incorporated into a single
particle. This observation suggests a high degree of ﬂexibil-
ity in the way the proteins associate with DMPC bilayers.
Notably, the sample analyzed here is prepared under con-
ditions of excess protein, which may promote the attachment
of more proteins onto the reconstituted particle. Indeed, in
samples prepared in excess DMPC, the C2 geometric group
has an even higher frequency (data not shown).
The heterogeneity of the reconstituted B6.4-17/DMPC
particles comes from the different combinations of proteins
assembled on the circumference of a DMPC bilayer (Fig. 8,
d–f). A head-to-tail arrangement will give rise to a symmetric
geometry of nanogold labels, such as C2 and C3 (Fig. 8, d and
f). A head-to-head assembly will result in nonsymmetrical
geometry, such as the one shown in Fig. 8 e. Another level of
heterogeneity can arise from the fact that some subdomains in
B6.4-17may detach fromDMPC.Wang and co-workers have
demonstrated that amphipathic b-sheets bind hydrophobic
surfaces irreversibly, while amphipathic a-helices may be
expelled when the interfacial pressure reaches a critical point
(38–40). Thus, the amphipathicb-sheets could outcompete the
weaker binding helical regions at the hydrophobic edge of the
particle.We suspect that not all lipid-binding elements inB6.4-
17 are associated with DMPC when the number of proteins in
the particle increases (Fig. 8 f). This adaptability in the protein
can give rise to particles with different number of proteins, but
a similar sized lipid core. This would also explain the
occasional observation of reconstituted particles with two
nanogold labels very close to each other (Fig. 6, #6 and #11).
The reconstituted B6.4-17/DMPC complexes appear
morphologically very similar to premature HDL particles
formed with apoA-I. However, our study indicates that the
N-terminal a-helical and C-sheet domains in apoB behave
differently in comparison with apoA-I. ApoA-I is one of the
major protein components in HDL. Structurally, lipid-free
apoA-I is believed to be a molten globule (41). The
formation of HDL-like particles by apoA-I involves signif-
icant conformational changes, which are manifested by
changes in the a-helical content (42), thermal (33,42,43) and
chemical stability (43), proteolytic patterns (44), and anti-
body accessibilities (45). This conformational ﬂexibility of
apoA-I is also reﬂected by the two drastically different apoA-
I crystal structures, showing either a fully extended pseudo-
continuous a-helical belt structure or a much more compact
six helices forming two helical bundles (46,47). In contrast to
apoA-I, the formation of a B6.4-17/DMPC particle does not
require signiﬁcant changes in either the a-helical content or
the chemical stability in the helical domain. A similar frag-
ment corresponding to a largely untouched a-helical domain
is observed during limited proteolysis of B6.4-17 in recon-
stituted DMPC complexes, which is different from the obser-
vation in apoA-I (44). Moreover, the minimal-sized B6.4-17/
DMPC complex has an average dimension of 152 A˚ in
diameter, while apoA-I makes discoidal particles as small as
60 A˚ in diameter (24,33). This difference may derive from
the rigidity of the B6.4-17 protein, which is a result of tighter
tertiary folding compared to the putative extended helix belt
model of apoA-I. Indeed, the molecular surface of two B6.4-
17 as shown in our model with minimal conformational ad-
justment already provides sufﬁcient hydrophobic interface
to cover the hydrocarbon chains in the DMPC complex. In
short, a completely extended helical belt model, which has
been proposed for apoA-I when the protein binds phospho-
lipid, does not ﬁt the observation made in B6.4-17.
The maintenance of a higher order tertiary structure during
phospholipid binding may correlate with the function of this
N-terminal apoB domain during lipoprotein assembly. Based
on the lipovitellin structure, we speculate that the N-terminal
half of the a-helical domain interacts with sequences be-
tween B17-20.5, which fold into another extended b-sheet,
termed the ‘‘A-sheet’’ in lipovitellin (48). The phospholipid
incorporation may be a cotranslational process, and the
N-terminal half of the a-helical domain may assist the sta-
bilization of a nascent initiation particle, when the proposed
A-sheet is absent. When the A-sheet is folded, it may ﬁnd its
position on the initiation particle through the interaction with
the N-terminal subdomain. Moreover, in the endoplasmic
reticulum, MTP, which is approximately the size of B17, is
also homologous to lipovitellin (11). MTP is proposed to be
a triglyceride-shuttling protein (19). Its less efﬁcient phos-
pholipid transferring activity was recently suggested to be
sufﬁcient for the assembly and secretion of apoB-containing
lipoproteins (21). However, no distinction between phos-
pholipid remodeling versus phospholipid transferring activ-
ity has been made experimentally. Since MTP is homologous
to B17, it may also have similar phospholipid remodeling
and binding properties. It is possible that the predominantly
dimeric assembly of B6.4-17 on a DMPC particle observed
in vitro is replaced by a similar apoB/MTP interaction during
lipoprotein assembly in vivo. Thus, MTP may play a struc-
tural role and stabilize a phospholipid-enriched initiating
particle when the nascent apoB polypeptide is incompetent
to fully encircle the trapped lipid moieties.
To fully elucidate the mechanism that initiates the forma-
tion of apoB-containing lipoproteins requires the establishment
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of in vitro systems containing apoB, MTP, and the lipid com-
ponents. The heterogeneous nature of such model systems
signiﬁcantly complicates the application of most structural
methods.With certain modiﬁcations, the direct imagingmethod
described here provides a viable strategy to examine the
structure of single lipoprotein particles at the molecular level,
and should facilitate the ultimate goal of understanding the in
vivo assembly of lipoproteins.
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